BMS-345541 inhibited nuclear factor kappa B expression and improved locomotor function recovery in rats after acute spinal cord injury

Neural Regeneration Research

Volumn 6, Issue 23, 2011, Pages 1775-1779

  Han, Xin ^a   Wang, Shouyu ^a   Zhang, Zhen ^a   Lü, Decheng ^a   Liu, Hairun ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

BMS 345541; Locomotor function; Neural regeneration; Nuclear factor kappa B; Spinal cord injury

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR RELA;

ACUTE DISEASE; ACUTE SPINAL CORD INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION REGULATION; HINDLIMB; LIMB DISEASE; LOCOMOTION; NONHUMAN; OUTCOME ASSESSMENT; RAT; SPINAL CORD INJURY; SUBDURAL DRUG ADMINISTRATION;

EID: 80053201732     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bethea JR, Castro M, Keane RW, et al. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci. 1998; 18(9):3251-3260.
2. Brambilla R, Bracchi-Ricard V, Hu WH, et al. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med. 2005; 202(1):145-156.
3. Rafati DS, Geissler K, Johnson K, et al. Nuclear factor-kappaB decoy amelioration of spinal cord injury-induced inflammation and behavior outcomes. J Neurosci Res. 2008;86(3):566-580.
4. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci. 1997;17(14):5395-5406.
5. Jiménez-Garza O, Camacho J, Ibarra A, et al. Early effects of modulating nuclear factor-kappaB activation on traumatic spinal cord injury in rats. Ann N Y Acad Sci. 2005;1053:148-150.
6. Conti A, Cardali S, Genovese T, et al. Role of inflammation in the secondary injury following experimental spinal cord trauma. J Neurosurg Sci. 2003;47(2):89-94.
7. Beck KD, Nguyen HX, Galvan MD, et al. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain. 2010;133(Pt 2):433-447.
8. Sribnick EA, Samantaray S, Das A, et al. Postinjury estrogen treatment of chronic spinal cord injury improves locomotor function in rats. J Neurosci Res. 2010;88(8):1738-1750.
9. Huxford T, Huang DB, Malek S, et al. The crystal structure of the IkappaB alpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell. 1998;95(6):759-770.
10. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004;5(5):392-401.
11. Sakurai H, Suzuki S, Kawasaki N, et al. Tumor necrosis factor- alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem. 2003;278(38):36916-36923.
12. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine- activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278(5339):860-866.
13. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem. 2003;278(3):1450-1456.
14. Sarnico I, Boroni F, Benarese M, et al. Targeting IKK2 by pharmacological inhibitor AS602868 prevents excitotoxic injury to neurons and oligodendrocytes. J Neural Transm. 2008;115(5): 693-701.
15. Sors A, Jean-Louis F, Bégué E, et al. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res. 2008;14(3):901-911.
16. Fuchs O. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol. 2010;3(3):98-122.
17. López-Guerra M, Roué G, Pérez-Galán P, et al. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541. Clin Cancer Res. 2009;15(8):2767-2776.
18. Yang J, Amiri KI, Burke JR, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res. 2006;12(3 Pt 1):950-960.
19. Grimaldo S, Tian F, Li LY. Sensitization of endothelial cells to VEGI-induced apoptosis by inhibiting the NF-kappaB pathway. Apoptosis. 2009;14(6):788-795.
20. MacMaster JF, Dambach DM, Lee DB, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res. 2003;52(12): 508-511.
21. Herrmann O, Baumann B, de Lorenzi R, et al. IKK mediates ischemia-induced neuronal death. Nat Med. 2005;11(12): 1322-1329.
22. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol. 1996;139(2): 244-256.
23. Pizzi M, Goffi F, Boroni F, et al. Opposing roles for NF-kappa B/Rel factors p65 and c-Rel in the modulation of neuron survival elicited by glutamate and interleukin-1beta. J Biol Chem. 2002; 277(23):20717-20723.
24. Zhang W, Potrovita I, Tarabin V, et al. Neuronal activation of NF-kappaB contributes to cell death in cerebral ischemia. J Cereb Blood Flow Metab. 2005;25(1):30-40.
25. Cho IH, Hong J, Suh EC, et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008; 131(Pt 11):3019-3033.
26. Zhang F, Qian L, Flood PM, et al. Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther. 2010;333(3):822-833.
27. Koopmans GC, Deumens R, Buss A, et al. Acute rolipram/ thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury. Exp Neurol. 2009;216(2): 490-498.
28. Herrmann JE, Imura T, Song B, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28(28):7231-7243.
29. Bracken MB, Shepard MJ, Hellenbrand KG, et al. Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg. 1985;63(5):704-713.
30. Paterniti I, Genovese T, Crisafulli C, et al. Treatment with green tea extract attenuates secondary inflammatory response in an experimental model of spinal cord trauma. Naunyn Schmiedebergs Arch Pharmacol. 2009;380(2):179-192.
31. Sribnick EA, Wingrave JM, Matzelle DD, et al. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res. 2005;82(2): 283-293.
32. Kerr BJ, Girolami EI, Ghasemlou N, et al. The protective effects of 15-deoxy-delta-(12,14)-prostaglandin J2 in spinal cord injury. Glia. 2008;56(4):436-448.
33. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
34. Yang L, Lü DC, Zheng LJ, et al. Neuroprotective effects of the immunodepressant FTY720 on caspase-3 expression and neural apoptosis in a rat model of acute spinal cord injury. Neural Regen Res. 2010;5(9):700-705.
35. Xu J, Fan G, Chen S, et al. Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res Mol Brain Res. 1998;59(2):135-142.
36. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995;12(1):1-21.